Ascentage Collaborates with UNITY on Treatments to Clear Senescent Cells

Ascentage Pharma of Shanghai will collaborate with San Francisco's UNITY Biotechnology using Acentage's apoptosis molecules to develop anti-senescence treatments for age-related disease. A clinical-stage biopharma, Ascentage has developed a library of small-molecule apoptosis molecules for oncology indications. UNITY is focused on developing drugs that clear senescent cells as treatments for age-related disease. Each company will make an investment in the other, though details were not disclosed. They will also form a JV to market senescence treatments in China. Ascentage will be attending the ChinaBio® Partnering Forum, May 18-19 in Suzhou. More details.... Share this with colleagues: // //